Page History
...
Committee Member | Present | Absent |
---|---|---|
X | ||
X | ||
X | ||
X | ||
X | ||
X | ||
Debbie Knapp | X | |
Toby Hecht | X | |
X |
Goals
- Discuss updates to ICDC and define emerging strategies and priorities
...
Item | Who | Talking Points |
---|---|---|
Steering Committee Meeting Updates | Unknown User (parchmentr) |
|
ICDC Next Phase |
| |
DGAB Updates |
| |
Data Use Guidelines |
| |
User Research for ICDC by the Office of Communications and Public Liaison (OCPL) | Kuffel, Gina (NIH/NCI) [C] |
|
ICDC Site Updates |
|
Minutes (Not Verbatim)
EK - Collected use cases in 2019 before any data was in ICDC. Around 8 use cases were documented. Many of the responses included high-level, overarching concepts. To uncover the real scientific use cases we nee do talk with PostDcos and Grad Students.
TH- Comparative Oncology community will be interested in specific questions.
EK- NCPI has a team comprised of NHLBI, NCI, Common Fund, and NHGRI to provide use cases of interoperability across the platforms and cloud resources. We are exploring congenital cancer in Gliomas, we might be able to add canine glioma data to identify any correlations that may exist. Use cases are in the works. We solicited researchers to get the scientific use cases.
TH- Longitudinal studies can be very useful in dogs. We can use that data to draw comparisons in humans. We will probably give some funding to the Dog Aging Study that may be matched by the Dog Aging Institute. They have ~30k dogs they are following, healthy dogs, many develop cancer. They are willing to sequence if they had the funding.
JO- Valuable just to have healthy, normal dogs as well. Could they be a source for deposit into ICDC?
TH- Reference standards are prolific at this point. There is a new canine reference German Shepherd 1.0 named Mischka.
Previous ICDC Use Cases from Steering Committee
1. Genomic correlates across platforms (DNA, RNA, protein).
2. Correlating multi-omics data with clinical annotation and phenotypes, particularly outcomes.
3. Comparative analyses of canine and human. Examples include:
1. Search for conserved mutations between canine and human tumors
2. Disease diagnosis (e.g. cancer type) and classification mapping between canines and humans
5. Gene expression changes and mutational profiles associated with therapeutic response and outcome
6. How do sporadic tumors in non-human mammals compare to sporadic human tumors?
7. Correlations and model building from radiomic and pathomic features extracted from medical and histopathologic images with outcomes and genomics, as is currently being widely done with human images
8. Develop biomarkers of response and resistance in humans by analyzing the responses and genomic signatures in dogs.
Previous Meeting Minutes (Not Verbatim)
...